Third-dose SARS-CoV-2 mRNA vaccine increases Omicron variant neutralization in patients with chronic myeloid disorders

Blood Adv. 2023 May 23;7(10):1954-1957. doi: 10.1182/bloodadvances.2022008375.

Patrick Harrington^{1

2}, Ashwini Kurshan³, Marc Delord⁴, Thomas Lechmere³, Amna Sheikh¹, Jamie Saunders¹, Chandan Saha¹, Richard Dillon^{1

5}, Claire Woodley¹, Susan Asirvatham¹, Natalia Curto-Garcia¹, Jennifer O' Sullivan¹, Shahram Kordasti^{1

2}, Deepti Radia¹, Donal McLornan^{1

6}, Michael H Malim³, Claire Harrison^{1

2}, Katie J Doores³, Hugues de Lavallade^{1

2}

¹ Department of Clinical Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
² School of Cancer and Pharmaceutical Science, King's College London, London, United Kingdom.
³ Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom.
⁴ Department of Population Health Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
⁵ Department of Medicine and Molecular Genetics, King's College London, London, United Kingdom.
⁶ Department of Clinical Haematology, University College Hospital, London, United Kingdom.

No abstract available

Publication types